Wedbush Maintains Outperform on Viridian Therapeutics, Raises Price Target to $47

Benzinga · 2d ago
Wedbush analyst Laura Chico maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $42 to $47.